<div id="readability-page-1"><div><p>(MT Newswires) -- China's medical product administrator approved Guangxi Wuzhou Zhongheng's (SHA:600252) nicorandil tablets and ketorolac tromethamine injection, according to a Thursday filing with the Shanghai bourse.</p><p> The nicorandil tablets are indicated for angina pectoris or chest pain, while the ketorolac tromethamine injection is indicated for post-operative pain relief, the filing said.</p><p>Shares fell 1% during afternoon trading on Thursday.</p></div></div>

中恒集团

<p>（MT Newswires）-- 根据周四在上海证券交易所的文件，中国医疗产品管理局批准了广西梧州中恒（SHA:600252）的硝苯地平片和酮咯酸托瑞米芬注射液。文件指出，硝苯地平片适用于心绞痛或胸痛，而酮咯酸托瑞米芬注射液适用于术后镇痛。周四下午交易中，股价下跌了 1%</p>

广西梧州中恒集团获得中国批准用于治疗胸部和术后疼痛的药物